Apoptotic caspases cut down the immunogenicity of radiation

Aitziber Buqué; Maria Esperanza Rodriguez-Ruiz; Jitka Fucikova; Lorenzo Galluzzi

doi:10.1080/2162402X.2019.1655364

Apoptotic caspases cut down the immunogenicity of radiation

Oncoimmunology. 2019 Aug 20;8(11):e1655364. doi: 10.1080/2162402X.2019.1655364. eCollection 2019.

Authors

Aitziber Buqué¹, Maria Esperanza Rodriguez-Ruiz^{1

2}, Jitka Fucikova^{3

4}, Lorenzo Galluzzi^{1

5

6

7}

Affiliations

¹ Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.
² Department of Radiation Oncology, University of Navarra Clinic and CIMA, Pamplona, Spain.
³ Sotio, Prague, Czech Republic.
⁴ Department of Immunology, Charles University, Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
⁵ Sandra and Edward Meyer Cancer Center, New York, NY, USA.
⁶ Department of Dermatology, Yale School of Medicine, New Haven, CT, USA.
⁷ Université Paris Descartes/Paris V, Paris, France.

Abstract

Caspases are known for their ability to precipitate apoptosis. Our findings indicate that accelerating the terminal inactivation of cells dying in response to radiation therapy limit their immunogenicity as a consequence of reduced type I interferon secretion. Thus, caspase inhibitors stand out as promising combinatorial partners to improve the immunogenicity of radiation therapy in the clinic.

Keywords: CASP3; CGAS; PGE2; SLC7A2; immune checkpoint blockers; mitochondrial outer membrane permeabilization.

Publication types

Research Support, U.S. Gov't, Non-P.H.S.
Research Support, Non-U.S. Gov't